July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Association between nonsteroidal anti-inflammatory drugs and uveitis recurrence in ankylosing spondylitis patients
Author Affiliations & Notes
  • Kaidi Wang
    UCSF/Proctor Foundation, San Francisco, California, United States
  • Lianne Gensler
    Rheumatology, UCSF, San Francisco, California, United States
  • Andrew Hirst
    UCSF/Proctor Foundation, San Francisco, California, United States
  • John D Reveille
    Rheumatology, The University of Texas Health Science Center at Houston, Houston, Texas, United States
  • Michael M Ward
    Clinical Trials and Outcomes Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, United States
  • Michael H Weisman
    Rheumatology , Cedars Sinai Medical Center, Los Angeles, California, United States
  • Matthew A Brown
    Queensland University of Technology, Queensland, Queensland, Australia
  • MinJae Lee
    Clinical and Translational Sciences, The University of Texas Health Science Center at Houston, Houston, Texas, United States
  • Mohammad Rahbar
    Clinical and Translational Sciences, The University of Texas Health Science Center at Houston, Houston, Texas, United States
  • Travis Porco
    UCSF/Proctor Foundation, San Francisco, California, United States
  • Nisha Acharya
    UCSF/Proctor Foundation, San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Kaidi Wang, None; Lianne Gensler, AbbVie (F), Amgen (F), Janssen (C), Novartis (C), UCB (F); Andrew Hirst, None; John Reveille, Eli Lilly (F), Janssen (F), Janssen (C), Pfizer (C), UCB (F); Michael Ward, None; Michael Weisman, Ampel Biosolutions, LLC (C), DOD/Immunomedics (F), Eli Lilly (F), EMD Serono (F), Genentech (F), Human Genome Sciences (F), Ionis Pharmaceuticals (C), UCB (F), UCB (C); Matthew Brown, AbbVie (F), AbbVie (C), AbbVie (S), Janssen (F), Janssen (C), Leo Pharma (F), Pfizer (C), Pfizer (S), UCB (F), UCB (S); MinJae Lee, None; Mohammad Rahbar, None; Travis Porco, None; Nisha Acharya, AbbVie (C), Santen, Inc (C)
  • Footnotes
    Support  NIAMS 4P01AR052915-10
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 421. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kaidi Wang, Lianne Gensler, Andrew Hirst, John D Reveille, Michael M Ward, Michael H Weisman, Matthew A Brown, MinJae Lee, Mohammad Rahbar, Travis Porco, Nisha Acharya; Association between nonsteroidal anti-inflammatory drugs and uveitis recurrence in ankylosing spondylitis patients. Invest. Ophthalmol. Vis. Sci. 2018;59(9):421.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line therapy for ankylosing spondylitis (AS). AS patients may develop acute anterior uveitis. While some report that NSAIDs may be helpful in preventing uveitic flares, there is limited data overall on their potential impact. The aim of this study was to assess the impact of oral NSAIDs on uveitis recurrence in AS patients.

Methods : We utilized a prospective longitudinal AS cohort. Standardized questionnaires were collected at baseline and every 6 months to assess the status of AS and uveitis and collect all systemic and topical medications used. Fisher exact tests were used to compare categorical variables. Patients were included in our analysis if they had a history of uveitis at baseline or if they developed incident uveitis during their follow-up. Recurrence was defined as uveitis occurring after this initial designation. Incidence rate of uveitis was also calculated. A mixed-effects longitudinal logistic regression model was used to look at the association of NSAIDS on the recurrence of uveitis, weighted by the inverse propensity scores of using NSAIDS, which were adjusted for age at baseline, follow-up time, B27 positivity, use of disease-modifying anti-rheumatic drugs (DMARDs), etanercept and all other TNF inhibitors and other biologics.

Results : 1024 AS patients were enrolled between 3/23/2007 and 10/13/2016. 460 (45%) were using oral NSAIDs at baseline. 331 (32%) had a diagnosis of uveitis at baseline and 56 developed uveitis during follow-up, resulting in a 3.8% risk of developing uveitis per person-year. See Table 1 for other baseline information. The weighted adjusted regression model found that patients with a history of uveitis who were using NSAIDS had a 26% lower odds of having a uveitis recurrence (odds ratio 0.74, 95% CI 10.2 - 39.4, p = 0.003).

Conclusions : In AS patients with a history of uveitis, oral NSAID use was associated with lower odds of a uveitis recurrence. NSAIDs could be considered as a potential treatment for preventing uveitis flare-ups.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×